Secukinumab fails the health technology assessment (HTA) in Germany in the context of the indication extension for hidradenitis suppurativa (HS). This example shows the high importance of comparative evidence in Germany. In addition, such evidence will even play a more important role in the upcoming Joint Clinical Assessments (JCA) on EU level from 2025 onwards.

Feel free to contact us for more detailed insights!

ISPOR Europe 2023 is coming. The GIPAM leadership team is looking forward to a sensational conference and many fruitful discussions.

Thomas Wilke is going to present current options and innovative approaches around Pay-for-Performance reimbursement solutions at the upcoming FoGes symposium in Munich on the 24th of October.

GIPAM has entered into a strategic partnership with Core Clinical Sciences.

CCS’s expertise in simulation and modeling for clinical trials as well as advanced analytics solutions will naturally complement our expertise in Strategic Market Access Consulting and Real-World Evidence studies at GIPAM.

That it is possible to obtain superior G-BA assessment grades was recently shown by Esketamin in therapy-resistant major moderate to severe depression.

Feel free to contact us for more detailed insights!

GIPAM tracks regularly published G-BA decisions on potential implications for future HTA/market access strategies. Ibrutinib, in combination with Venetoclax, was a recent assessment (July 2023) that has important strategic implication..

Feel free to contact us for more detailed insights!

We are excited to announce that our new European consultancy, GIPAM, became operational on the 1st of September, and along with it, we are more than happy to release our website.

Together with the ZKN institute at the University of Dresden and the German sickness fund AOK PLUS, a data set that links claims data since 2010 for more than 500 patients with all their relevant clinical MS data (medical record data) has been generated.